Skip to main content
Open Access Publications from the University of California


UCLA Previously Published Works bannerUCLA

Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis.

  • Author(s): Barjaktarevic, Igor Z
  • Buhr, Russell G
  • Wang, Xiaoyan
  • Hu, Scott
  • Couper, David
  • Anderson, Wayne
  • Kanner, Richard E
  • Paine Iii, Robert
  • Bhatt, Surya P
  • Bhakta, Nirav R
  • Arjomandi, Mehrdad
  • Kaner, Robert J
  • Pirozzi, Cheryl S
  • Curtis, Jeffrey L
  • O'Neal, Wanda K
  • Woodruff, Prescott G
  • Han, MeiLan K
  • Martinez, Fernando J
  • Hansel, Nadia
  • Wells, James Michael
  • Ortega, Victor E
  • Hoffman, Eric A
  • Doerschuk, Claire M
  • Kim, Victor
  • Dransfield, Mark T
  • Drummond, M Bradley
  • Bowler, Russell
  • Criner, Gerard
  • Christenson, Stephanie A
  • Ronish, Bonnie
  • Peters, Stephen P
  • Krishnan, Jerry A
  • Tashkin, Donald P
  • Cooper, Christopher B
  • NHLBI SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS)
  • et al.


Bronchodilator responsiveness (BDR) is prevalent in COPD, but its clinical implications remain unclear. We explored the significance of BDR, defined by post-bronchodilator change in FEV1 (BDRFEV1) as a measure reflecting the change in flow and in FVC (BDRFVC) reflecting the change in volume.


We analyzed 2974 participants from a multicenter observational study designed to identify varying COPD phenotypes (SPIROMICS). We evaluated the association of BDR with baseline clinical characteristics, rate of prospective exacerbations and mortality using negative binomial regression and Cox proportional hazards models.


A majority of COPD participants exhibited BDR (52.7%). BDRFEV1 occurred more often in earlier stages of COPD, while BDRFVC occurred more frequently in more advanced disease. When defined by increases in either FEV1 or FVC, BDR was associated with a self-reported history of asthma, but not with blood eosinophil counts. BDRFVC was more prevalent in subjects with greater emphysema and small airway disease on CT. In a univariate analysis, BDRFVC was associated with increased exacerbations and mortality, although no significance was found in a model adjusted for post-bronchodilator FEV1.


With advanced airflow obstruction in COPD, BDRFVC is more prevalent in comparison to BDRFEV1 and correlates with the extent of emphysema and degree of small airway disease. Since these associations appear to be related to the impairment of FEV1, BDRFVC itself does not define a distinct phenotype nor can it be more predictive of outcomes, but it can offer additional insights into the pathophysiologic mechanism in advanced COPD.

Clinical trials registration NCT01969344T4.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
Current View